Cargando…
Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma
The prognosis of advanced mesothelioma is poor. Podoplanin (PDPN) is highly expressed in most malignant mesothelioma. This study aimed to evaluate the potential alpha-radioimmunotherapy (RIT) with a newly developed anti-PDPN antibody, NZ-16, compared with a previous antibody, NZ-12. Methods: The in...
Autores principales: | Sudo, Hitomi, Tsuji, Atsushi B., Sugyo, Aya, Kaneko, Mika K., Kato, Yukinari, Nagatsu, Kotaro, Suzuki, Hisashi, Higashi, Tatsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533940/ https://www.ncbi.nlm.nih.gov/pubmed/34685483 http://dx.doi.org/10.3390/cells10102503 |
Ejemplares similares
-
Therapeutic efficacy evaluation of radioimmunotherapy with (90)Y‐labeled anti‐podoplanin antibody NZ‐12 for mesothelioma
por: Sudo, Hitomi, et al.
Publicado: (2019) -
Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent (211)At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice
por: Sudo, Hitomi, et al.
Publicado: (2019) -
Antitumor effect of novel anti‐podoplanin antibody NZ‐12 against malignant pleural mesothelioma in an orthotopic xenograft model
por: Abe, Shinji, et al.
Publicado: (2016) -
Detection of Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM) with the “Universal” CTC-Chip and An Anti-Podoplanin Antibody NZ-1.2
por: Kuwata, Taiji, et al.
Publicado: (2020) -
FZD10‐targeted α‐radioimmunotherapy with (225)Ac‐labeled OTSA101 achieves complete remission in a synovial sarcoma model
por: Sudo, Hitomi, et al.
Publicado: (2021)